|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02126 JW THERAP-B
Nominal 
5.100 -0.030 (-0.585%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 106,346 | 22.497% | 158,218 | 173,856 | 145,702 | 30,797 |
| Cost of Sales | (41,229) | -4.274% | (80,902) | (85,637) | (86,946) | (21,752) |
| Gross Profit | 65,117 | 48.856% | 77,316 | 88,219 | 58,756 | 9,045 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | 51,151 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (267,265) | 11.237% | (590,624) | (767,996) | (846,135) | (702,328) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (267,265) | 11.237% | (590,624) | (767,996) | (846,135) | (702,328) | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (6,177) | -14.753% | (16,211) | (21,611) | (9,748) | (5,604) |
| Depreciation & Amortisation | 31,950 | -3.067% | 77,244 | 78,673 | 84,810 | 45,648 |
| Directors' Emoluments | 829 | -- | 24,680 | 22,833 | 32,981 | 47,163 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -64.000 | 10.345% | -143.000 | -187.000 | -206.000 | -176.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.806) | (0.968) | (1.309) | (1.404) |
| NBV per share ($) | 2.183 | -- | 2.814 | 4.083 | 5.728 | 6.847 |
| Remarks: | Real time quote last updated: 11/09/2025 17:29 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -267,265 |
| %Change | 11.237% |
| EPS / (LPS) | RMB -0.640 |
| NBV Per Share (¥) | RMB 2.183 |